Pharmaceuticals

YONGAN PHARMACEUTICAL

YONGAN PHARMACEUTICAL released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 235.9 M, actual EPS CNY 0.0268

YONGAN PHARMACEUTICAL FY2026 Q1 Earnings Release on April 30 After-Market (BJT)

YONGAN PHARMACEUTICAL released FY2025 Q4 earnings on April 16 After-Market (BJT), actual revenue CNY 206.02 M, actual EPS CNY -0.0104

YONGAN PHARMACEUTICAL released FY2025 annual earnings on April 16 After-Market (BJT), actual revenue CNY 783.17 M, actual EPS CNY 0.0776

YONGAN PHARMACEUTICAL to Release FY2025 Earnings on April 17 After-Market BJT

YONGAN PHARMACEUTICAL released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 209.77 M, actual EPS CNY 0.0449

YONGAN PHARMACEUTICAL released FY2025 9 Months Earnings on October 29 After-Market BJT, actual revenue CNY 577.15 M, actual EPS CNY 0.088

YONGAN PHARMACEUTICAL to Release FY2025 Q3 Earnings on October 30 After-Market BJT

YONGAN PHARMACEUTICAL released FY2025 Q2 earnings on August 27 Pre-Market BJT, actual revenue CNY 196.22 M, actual EPS CNY 0.0582

YONGAN PHARMACEUTICAL released FY2025 Semi-Annual earnings on August 27 Pre-Market BJT, actual revenue CNY 367.38 M, actual EPS CNY 0.0431

YONGAN PHARMACEUTICAL to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Yongan Pharmaceutical Shareholder Plans to Reduce Holdings

Yongan Pharmaceutical's CSO Outlines Future Product Plans

Yongan Pharmaceutical Announces Significant Decline in Net Profit in Half-Year Forecast

Yongan Pharmaceutical Announces Projected Net Profit Decline for H1 2025

Yongan Pharmaceutical Secretary Responds to Investor Questions about Subsidiary and Earnings

Yongan Pharmaceutical's ESG Rating Result Announced

Yongan Pharmaceutical Secretary Responds to Adequate Production Capacity for Easy+ L-Taurine Effervescent Granules

Yongan Pharmaceutical down 5.88%, institutional seats net sell 105 million yuan

Investor Suggests Yong'an Medicine to Engage Shareholders in Product Promotion

002365

According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 577 million yuan, a year-on-year decrease of 6.72%. The net profit attributable to shareholders of the listed company was 25.4963 million yuan, a year-on-year decrease of 58.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 5.1844 million yuan, a year-on-year decrease of 86.17%

Zhitong

YONGAN PHARMACEUTICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 25.4963 million yuan, a year-on-year decrease of 58.78%

YONGAN PHARMACEUTICAL announced that its revenue for the third quarter was 210 million yuan, an increase of 8.75% year-on-year; net profit was 13.0005 million yuan, an increase of 38.75% year-on-year. Revenue for the first three quarters was 577 million yuan, a decrease of 6.72% year-on-year; net profit was 25.4963 million yuan, a decrease of 58.78% year-on-year

YONGAN PHARMACEUTICAL: Net profit for the third quarter was 13.0005 million yuan, a year-on-year increase of 38.75%

YONGAN PHARMACEUTICAL announced that the company plans to use its own funds of 27 million yuan to acquire a total of 49.20% equity in Ling'an Technology Co., Ltd. held by minority shareholders Zhang Yong, Xia Changpei, and Dai Liang, who are part of its controlling subsidiary in Hubei. This move aims to further strengthen control over Ling'an Technology, accelerate its market layout in the business field, and align with the company's overall strategic planning. After the transaction is completed, Ling'an Technology will become a wholly-owned subsidiary of the company. The source of funds is from its own resources and will not affect the company's normal production and operations

YONGAN PHARMACEUTICAL: Plans to acquire minority shareholder equity in its controlling subsidiary for 27 million yuan

YONGAN PHARMACEUTICAL announced that its controlling shareholder's concerted actor, Huanggang Yongan, reduced its holdings by 410,000 shares through centralized bidding on September 4, 2025, accounting for 0.1391% of the total share capital. After this equity change, the company's controlling shareholders, actual controllers, and their concerted actors collectively hold 73,587,200 shares, accounting for 24.9717%, reaching a multiple of 5%

YONGAN PHARMACEUTICAL: Controlling shareholder reduces holdings by 410,000 shares

According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL announced that the company's actual controller and chairman, Mr. Chen Yong, was previously investigated by the Hefeng County Supervisory Committee and was subjected to detention. Recently, the company received a notification from Mr. Chen Yong's family that they received the "Notice of Lifting Detention" issued by the Hefeng County Supervisory Committee, which has lifted the detention measures against Mr. Chen Yong

YONGAN PHARMACEUTICAL's actual controller Chen Yong lifts the lien

YONGAN PHARMACEUTICAL released its semi-annual report for 2025, reporting an operating income of 367 million yuan, a year-on-year decrease of 13.72%; net profit attributable to shareholders was 12.4957 million yuan, a year-on-year decrease of 76.19%; net profit after deducting non-recurring gains and losses was 2.2853 million yuan, a year-on-year decrease of 93.65%; basic earnings per share were 0.0432 yuan

YONGAN PHARMACEUTICAL released its performance for the first half of the year, with a net profit attributable to the parent company of 12.4957 million yuan, a year-on-year decrease of 76.19%

YONGAN PHARMACEUTICAL announced that its wholly-owned subsidiary YONGAN KANGJIAN PHARMACEUTICAL CO., LTD. has been re-certified as a high-tech enterprise. YONGAN KANGJIAN received the "High-tech Enterprise Certificate" jointly issued by the Hubei Provincial Department of Science and Technology, the Hubei Provincial Department of Finance, and the State Administration of Taxation Hubei Provincial Taxation Bureau, with certificate number GR202442005101, issued on December 24, 2024, and valid for three years. Since being certified as a high-tech enterprise, YONGAN KANGJIAN can continue to enjoy a preferential corporate income tax rate of 15% for three consecutive years

YONGAN PHARMACEUTICAL: Subsidiary re-certified as a high-tech enterprise

According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL announced that its controlling shareholder and actual controller, the concerted actor Huanggang Yongan Pharmaceutical Co., Ltd. (hereinafter referred to as "Huanggang Yongan"), plans to reduce its holdings of the company's shares by no more than 2.6323 million shares (accounting for 0.91% of the total share capital after excluding shares in the company's repurchase special account) through centralized bidding or block trading within three months after fifteen trading days from the date of this announcement

One of the actual controllers of YONGAN PHARMACEUTICAL, Huanggang Yongan, intends to reduce its holdings by no more than 0.91% of the shares

300468

300950

001287

688197

605500

Multiple high-priced stocks experienced adjustments today, with Forest Packaging and Forms Syntron dropping over 8%, DORIGHT and YONGAN PHARMACEUTICAL falling over 7%, and CECport and Shouyao Holdings among several stocks declining over 5%

Forms Syntron

DORIGHT

CECport

Shouyao Holdings

Forest Packaging

Multiple high-priced stocks experienced adjustments today, with Forest Packaging and Forms Syntron dropping over 8%

On July 16th, YONGAN PHARMACEUTICAL stated on the interactive platform that the price of taurine, after experiencing a three-year adjustment, stopped falling and began to rebound in May of this year. However, the price increase is a gradual process. According to the company's 2025 semi-annual performance forecast, the company's performance in the first half of the year has significantly declined compared to the same period last year, mainly due to the impact of a sluggish market, resulting in a decrease in both the production and sales volume and sales price of the company's main product, taurine, compared to the same period last year

YONGAN PHARMACEUTICAL: The price of taurine stopped falling in May and began to rebound, but the price increase is a gradual process

YONGAN PHARMACEUTICAL(002365.SZ)